StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.19+0.04 (+0.10%)

Close on Nov 18, 2026Market cap $3.89BP/E –Yield –

CRISPR Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

CRISPR Therapeutics's pe ratio was 20.4× on Jul 29, 2022, against 199.6× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jul 29, 202220.4×+4.5
2021Dec 31, 202115.9×−183.7
2020Oct 30, 2020199.6×–

More CRISPR Therapeutics figures

See a number that looks wrong?